Patent intelligence · US
US 10835505
Oral pharmaceutical formulation for weight loss, diabetes and related disorders
Oral pharmaceutical formulation for weight loss, diabetes and related disorders
Patent details — US 10835505
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 17, 2020
- Expiration
- Nov 12, 2040
- Applicant
- Aardvark Therapeutics, Inc.
- Claims
- 19
- CPC classes
- A61K, A61K31/165, A61K31/192, A61K31/365
Quick answer
US 10835505 (Oral pharmaceutical formulation for weight loss, diabetes and related disorders) is held by Aardvark Therapeutics, Inc.. Status: granted. Granted Nov 17, 2020. Expires Nov 12, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Aardvark Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 19
- CPC classes
- A61K, A61K31/165, A61K31/192, A61K31/365, A61P, A61P3/04
More from Aardvark Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12427125
Method for treating SARS and treating or preventing ARDS
granted -
US 12414934
Combination therapies
granted -
US 12329739
Isoflavonoid compounds and methods for the treatment of cancer
granted -
US 12318364
Isoflavonoid compositions and methods for the treatment of cancer
granted -
US 12268660
Oral pharmaceutical formulations of bitter compounds for pulmonary hypertension
granted -
US 12201593
Oral pharmaceutical formulations of bitter compounds for asthma
granted
Frequently asked questions
What is US patent 10835505?
US 10835505 (Oral pharmaceutical formulation for weight loss, diabetes and related disorders) is held by Aardvark Therapeutics, Inc.. Status: granted. Granted Nov 17, 2020. Expires Nov 12, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10835505?
Aardvark Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 7 pharmaceutical patents for this assignee.
When does US 10835505 expire?
Our index shows an expiration date of Nov 12, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.